^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    AXL overexpression + EGFR mutation

    i
    Other names: AXL Receptor Tyrosine Kinase, Tyrosine Protein Kinase Receptor UFO, AXL Oncogene, AXL Transforming Sequence Gene, Tyro7, EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956; 558
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    9ms
    Roles of p53 and AXL Expressions on the Efficacy of ICI-Based Therapy in Patients with EGFR Mutated Lung Cancer after Osimertinib (IASLC-WCLC 2023)
    Tumor protein-based analysis showed that p53 levels may be a predictive factor for clinical outcomes after ICI-based therapy in patients with EGFR-mutant NSCLC. Furthermore, AXL levels in tumors may be a predictor of ICI-based therapy outcomes, specifically for patients with common EGFR mutations. Further prospective large-scale investigations are warranted to confirm the effects of the expression of tumor p53 and AXL on clinical outcomes after ICI-based therapy.
    Clinical • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • AXL (AXL Receptor Tyrosine Kinase)
    |
    TP53 mutation • EGFR mutation • EGFR L858R • EGFR expression • AXL expression • TP53 expression • AXL overexpression + EGFR mutation
    |
    Tagrisso (osimertinib)
    1year
    Clinical impact of p53 and AXL immunostaining on the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor mutant non-small cell lung cancer (AACR 2023)
    The levels of p53 in pretreatment tumors may be a predictor of ICI-based therapy outcomes in patients with EGFR-mutant NSCLC after osimertinib treatment. High levels of AXL in tumors may also be a predictor of ICI-based therapy outcomes, specifically for patients with common EGFR mutations. Further prospective large-scale investigations on the predictors of ICI efficacy following osimertinib treatment are warranted.
    Clinical • Checkpoint inhibition • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • AXL (AXL Receptor Tyrosine Kinase)
    |
    TP53 mutation • EGFR mutation • EGFR L858R • EGFR expression • AXL expression • TP53 expression • AXL overexpression + EGFR mutation
    |
    Tagrisso (osimertinib)